Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
Titel:
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
Auteur:
Rao, S. Starling, N. Cunningham, D. Sumpter, K. Gilligan, D. Ruhstaller, T. Valladares-Ayerbes, M. Wilke, H. Archer, C. Kurek, R. Beadman, C. Oates, J.